Genetically modified non-human animals and methods of use thereof
Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.
1. A method of generating a mouse model of human B cell development and function, the method comprising:
transplanting a population of human hematopoietic cells into a genetically Rag2 −/− , IL2rg null modified mouse that is immunodeficient and comprises in its genome a nucleic acid encoding human IL-6 operably linked to the endogenous mouse IL-6 promoter at the mouse IL-6 locus, wherein the mouse expresses human IL-6 and does not express mouse IL-6, and wherein the mouse produces human B cells.
2. The method of claim 1 , wherein the transplanted population of hematopoietic cells comprises CD34+ cells.
3. The method of claim 1 , wherein the transplanted population of hematopoietic cells comprises multiple myeloma cells.
4. The method of claim 1 , wherein the transplanting comprises intrafemoral and/or intratibial injection.
5. The method of claim 1 , wherein the mouse further comprises in its genome a nucleic acid encoding human SIRPa, or a nucleic acid encoding a fusion protein comprising a biologically active fragment of a full length human SIRPA polypeptide, operably linked to a SIRPa promoter.
6. The method of claim 5 , wherein the SIRPa promoter is the mouse SIRPa promoter, and the nucleic acid encoding human SIRPa, or the nucleic acid encoding a fusion protein comprising a biologically active fragment of a full length human SIRPA polypeptide, is operably linked to the mouse SIRPa promoter at the mouse SIRPa locus.
7. The method of claim 1 , wherein the mouse comprises in its genome at least one additional nucleic acid selected from the group consisting of:
i) a nucleic acid encoding human M-CSF operably linked to a M-CSF promoter;
ii) a nucleic acid encoding human IL-3 operably linked to an IL-3 promoter;
iii) a nucleic acid encoding human GM-CSF operably linked to a GM-CSF promoter; and
iv) a nucleic acid encoding human TPO operably linked to a TPO promoter.
8. The method of claim 7 , wherein the M-CSF promoter is the mouse M-CSF promoter, and the nucleic acid encoding human M-CSF is operably linked to the mouse M-CSF promoter at the mouse M-CSF locus, the IL-3 promoter is the mouse IL-3 promoter, and the nucleic acid encoding human IL-3 is operably linked to the mouse IL-3 promoter at the mouse IL-3 locus, the GM-CSF promoter is the mouse GM-CSF promoter, and the nucleic acid encoding human GM-CSF is operably linked to the mouse GM-CSF promoter at the mouse GM-CSF locus, and the TPO promoter is the mouse TPO promoter, and the nucleic acid encoding human TPO is operably linked to the mouse TPO promoter at the mouse TPO locus.
9. The method of claim 1 , wherein the transplanting comprises injecting the population of human hematopoietic cells into the liver of the mouse.
10. The method of claim 3 , wherein the human multiple myeloma cells are INA6 cells.